Curefini Ointment
FDA Label NDC 79974-202

Full FDA labeling including Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Miramar Cosmetics, Inc Dba Miramar Lab for the product Curefini (NDC 79974-202). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding drug facts:, active ingredients:, purpose:, uses:, warnings:, otc - keep out of reach of children, other information:, directions:, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Drug Facts:

Active Ingredients:

Petrolatum 30.00%
Cod Liver Oil 10.00% 

Purpose:

Skin Protectant

Uses:

• Temporarily protects minor cuts, scrapes and burns. • Temporarily protects chapped or cracked skin. • Helps protect from drying effects of wind and cold weather.

Warnings:

• For external use only. • When using this product, do not get into eyes. • If condition worsens or does not improve for seven days, discontinue use and consult a physician.
• DO NOT USE IF TAMPER EVIDENT SEAL IS BROKEN.

Otc - Keep Out Of Reach Of Children

Keep out of reach of children. If swallowed, contact physician or poison control center immediately. Other Information: Store at room temperature.

Other Information:

Store at room temperature.

Directions:

Apply as needed. Prepare a gauze bandage to apply. Dressing should be placed on a clean and flat surface. Apply ointment with a spatula, covering the entire surface with a thin layer. Place bandage directly on top of affected area. Make sure affected area remains covered by ointment.

Inactive Ingredients:

Beeswax, BHT, Chamomilla Recutita (Chamomile) Oil, Helianthus Annuus (Sunflower) Oil, Prunus Amygdalus Dulcis (Sweet Almond) Oil.

Packaging

Curefiniointment (79974 202 16)

Curefiniointment (79974 202 16)

* Please review the disclaimer below.